SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
23. Januar 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
06. November 2024 17:05 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
31. Oktober 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
13. September 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
09. September 2024 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB BIO presents clinical trial progress update at EASD conference
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
04. September 2024 07:05 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
08. August 2024 17:51 ET
|
SAB Biotherapeutics, Inc.
FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO...
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
05. August 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
SAB BIO Appoints Lucy To as Chief Financial Officer
31. Juli 2024 07:30 ET
|
SAB Biotherapeutics, Inc.
SAB BIO Appoints Lucy To as Chief Financial Officer
SAb Biotherapeutics Rebrands as SAB BIO
20. Juni 2024 07:20 ET
|
SAB Biotherapeutics, Inc.
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE...